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Abstract In this study, we will propose a density esti-
mation based data analysis procedure to investigate the
co-morbid associations between migraine and the suspected
diseases. The primary objective of this study has aimed to
develop a novel analysis procedure that can discover
insightful knowledge from large medical databases. The
entire analysis procedure consists of two stages. During the
first stage, a kernel density estimation algorithm named
relaxed variable kernel density estimation (RVKDE) is
invoked to identify the samples of interest. Then, in the
second stage, a density estimation algorithm based on
generalized Gaussian components and named G2DE is
invoked to provide a summarized description of the distri-
bution. The results obtained by applying the proposed two-
staged procedure to analyze co-morbidities of migraine
revealed that the proposed procedure could effectively
identify a number of clusters of samples with distinctive
characteristics. The results further revealed that the dis-
tinctive characteristics of the clusters extracted by the
proposed procedure were in conformity with the observa-
tions reported in recently published articles. Accordingly, it
is conceivable that the proposed analysis procedure can be
exploited to provide valuable clues of pathogenesis and
facilitate development of proper treatment strategies.
Keywords Density estimation algorithm  Migraine 
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1 Introduction
In recent years, data analysis based on large medical and
clinical databases has gained attention among biomedical
researchers (Himes et al. 2009; Lai et al. 2010; Lugardon
et al. 2007). One major merit of this type of studies is that
these databases collect cases with good demographic
diversity. In addition, researchers can expeditiously verify
their hypotheses since they do not need to spend a signif-
icant amount of efforts to recruit cases. Nevertheless, most
studies have been conducted with conventional bio-statis-
tical approaches. Accordingly, scientists have turned to
exploit advanced machine learning and/or data mining
approaches to extract valuable clues hidden in large med-
ical and clinical databases (Himes et al. 2009; Lancashire
et al. 2005; Li et al. 2004; Niederkohr and Levin 2005). For
example, the Bayesian network has been exploited to
identify the co-morbidity between chronic obstructive
pulmonary disease and asthma (Himes et al. 2009). Fur-
thermore, the decision tree algorithm has been exploited to
guide diagnostic interpretation and therapeutic options for
temporal arteritis (Niederkohr and Levin 2005).
Electronic supplementary material The online version of this
article (doi:10.1007/s13721-013-0028-8) contains supplementary
material, which is available to authorized users.
M.-H. Yang (&)
Department of Computer Science and Information Engineering,
National Kaohsiung University of Applied Sciences,
No. 415 Chien Kung Rd., Kaohsiung 80778, Taiwan, ROC
e-mail: d95922001@ntu.edu.tw; menghanyang@kuas.edu.tw
F.-Y. Yang
The Department of Neurology, Taipei Tzu Chi General Hospital,




Department of Computer Science and Information Engineering,
National Taiwan University, No. 1, Sec. 4, Roosevelt Rd.,
Taipei City 10617, Taiwan, ROC
e-mail: yjoyang@csie.ntu.edu.tw
123
Netw Model Anal Health Inform Bioinforma (2013) 2:95–107
DOI 10.1007/s13721-013-0028-8
In our study, we have aimed to exploit density estimation
algorithms in the analysis of large medical/clinical dat-
abases. Density estimation is a classical problem in statis-
tics aimed at constructing an approximate probability
density function based on the samples randomly and inde-
pendently taken from an underlined distribution. In the
proposed approach, we have exploited the relaxed variable
kernel density estimation (RVKDE) algorithm (Oyang et al.
2005) and the generalized Gaussian component based
density estimation (G2DE) algorithm (Hsieh et al. 2009)
that our research team has developed in recent years. The
RVKDE algorithm has been exploited to identify those case
samples that share some distinctive features in comparison
with the control samples. Then, the G2DE algorithm has
been invoked to provide a summarized and highly inter-
pretable description of the underlying distribution.
In our study, aiming to learn the actual effects of the
proposed analysis procedure, we have applied the proposed
procedure to analyze co-morbidities of migraine. Migraine
is a prevalent neurological disorder whereby patients suffer
from recurrent headache attacks, nausea, photophobia, and
phonophobia. Recent demographical studies showed that
migraine was more common to women than to men and its
burden has been underestimated. Many illnesses, physical
or psychiatric, have been reported to be co-morbid with
migraine (Aamodt et al. 2007; Bigal et al. 2010; Buse et al.
2010; Hagen et al. 2002; Kurth et al. 2008; Le et al. 2011);
these disorders occur at a greater coincidental rate among
migraine patients than among the general population.
Understanding the association of migraine with other
health conditions can help the clinicians providing better
care and investigate the pathogenesis of these disorders.
2 Methods
2.1 Density estimation algorithms
In this section, we will elaborate the main features of the
RVKDE algorithm and the G2DE algorithm exploited in
the proposed analysis procedure and the desired effects
achieved. Basically, the RVKDE algorithm was designed
to construct an approximate probability density function
with high accuracy. On the other hand, the G2DE algorithm
was designed to provide a summarized and highly inter-
pretable description of the underlying distribution.
Let {s1, s2, …, sn} be a set of samples randomly and
independently taken from the distribution governed by
probability density function f in a d-dimensional vector
space. Then, the RVKDE algorithm constructs an approx-
imate probability density function f^ based on the following
general form:




















p , R(si) is the maximum distance
between si and its k nearest training instances; C() is the
gamma function (Artin 1964); b and k are parameters to be
set either through cross validation or by the user.
The general form of the RVKDE algorithm indicates
that, for each sample, a Gaussian function is placed at its
corresponding coordinates in the vector space. Accordingly,
the approximate function constructed by the RVKDE
algorithm is composed of a large number of Gaussian
functions and it is difficult for a user to gain an abstract
image of the underlying distribution in a multiple-dimen-
sion vector space. Therefore, our research team has
designed the G2DE algorithm to provide the complementary
feature. The approximate function constructed by the G2DE
algorithm is composed of a limited number of generalized
Gaussian components as shown in the following:
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ðv  liÞÞ, d is the dimension of the vector space,
wi; li; and Ri are the weight, center, and the covariance
matrix of the i-th Gaussian component, respectively.
Since each Gaussian component in a G2DE based
probability model corresponds to a cluster of samples, we
can examine the centers and the covariance matrices of the
Gaussian components to obtain an abstract image of the
underlying distribution. Nevertheless, it must be noted that
the number of parameters in a G2DE based probability
model is equal to
kðdþ2Þðdþ1Þ
2
. As a result, if we do not set
k and d to small integers, then we need to examine a large
number of parameter values and it may be difficult for us to
interpret the physical meanings of the parameter values.
2.2 The clinical database
The study reported in this article has been conducted based
on the Research Database released by the National Health
Insurance Program in Taiwan. The National Health Insur-
ance (NHI) program in Taiwan was launched in 1995 and
as in December 2010 covered about 23,074,000 insurants,
which accounted for over 99 % of the entire population in
Taiwan. In addition, almost all medical hospitals and
clinics in Taiwan have joined the program. As in December
2010, there were 25,031 medical institutes enrolled in the
program. Since 2000, the Bureau of the program began to
release the National Health Insurance Research Database
(NHIRD) to facilitate medical research. The updated
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version used in this study contains the ambulatory and
hospitalization claims records of 1,000,000 randomly
selected insurants over the period from 1996 to 2010
without significant difference in age, sex, and insurance
cost relative to the whole population.
2.3 Case patient definition and control selection
The cases in this study include those patients who were
diagnosed with migraine in outpatient and/or inpatient
records during 2004–2008. The ICD-9 CM codes (Inter-
national Classification of Disease, 9th Revision, Clinical
Modification; http://icd9cm.chrisendres.com/) used for
screening include 346.09, 346.19, 346.89, and 346.99,
which correspond to patients with migraine with or without
aura. In our study, for each migraine case, five controls
without any migraine record during 1996–2010 and with
matched gender and age were randomly selected from the
NHIRD. As a result, the cohort contained 19,356 migraine
cases and 96,780 controls. For a case, the date of the first
migraine diagnosis was defined to be the index date and the
same index date was assigned to the matched controls.
2.4 Medication exposure utilized as features
In our analysis, each cohort subject was associated with a
feature vector that recorded the exposure of the subject to the
commonly used medications for migraine treatment during
the study period, including amitriptyline, flunarizine, pro-
pranolol, topiramate, and valproic acid. The exposure was
measured by the number of days and the dosage in milli-
grams. The dosage was also calculated in defined daily dose
(DDD) by World Health Organization (http://www.whocc.
no/atc_ddd_index/) for validation. The exposure to each
category of medications was counted separately. Accord-
ingly, the feature vector is composed of ten elements. In our
analysis, we further normalized the feature values corre-
sponding to the same element in the feature vector by
applying the standard min–max normalization.
The five categories of drugs for migraine treatment
mentioned above all belong to preventive medicines.
Aiming to validate drug medications of our study popula-
tion, we also analyzed the prescription orders for ergota-
mine during the study period, which is a frequent relief
treatment of migraine attacks.
2.5 Diseases utilized as outcomes
Our study focused on those diseases that had been reported
to be the co-morbidities of migraine (Aamodt et al. 2007;
Bigal et al. 2010; Buse et al. 2010; Hagen et al. 2002;
Le et al. 2011). These diseases can be classified into six
categories as follows based on the ICD-9 CM codes:
1. Mental disorders: alcohol abuse (ICD-9 CM codes:
265.2, 291.xx, 303.xx, 305.0x, 357.5, 425.5, 535.3x,
571.0, 571.1, 571.3, 980.x, and V113); anxiety state
(codes: 300.00, 300.02, and 300.09); bipolar disorder
(codes: 296.0x, 296.1x, 296.4x, and 296.6x–296.9x);
depression (codes: 296.2x, 296.3x, 296.5x, 300.4,
309.xx, and 311); drug abuse (codes: 292.xx, 304.xx,
305.2x–305.9x, and V6542); psychoses (codes:
293.8x, 295.xx, 297.x, and 298.x)
2. Otolaryngology: allergic rhinitis (ICD-9 CM codes:
477.x); chronic pulmonary disease (codes: 490–496,
500–505, and 506.4); Meniere’s disease (codes: 386.0x)
3. Musculoskeletal illnesses: low back pain (ICD-9 CM
codes: 724.xx); neck pain (code: 723.1); neck sprain
(code: 847.0); pain syndrome (codes: 719.4x and 729.1);
rheumatoid arthritis (codes: 446.x, 701.0, 710.2, 710.3,
710.8, 710.9, 711.2x, 714.3x, 714.4, 714.89, 714.9,
719.3x, 720.xx, 728.5, 728.89, and 729.30); spinal disk
herniation (codes: 722.0–722.2, and 722.7x);
4. Metabolism and endocrinology: diabetes mellitus
(ICD-9 CM codes: 250.0x–250.3x, and 250.7x); fluid
electrolyte disorder (codes: 253.6 and 276.x); hyperlip-
idemia (codes: 272.x); hypothyroidism (codes: 240.9,
243, 244.x, 246.1, and 246.8); obesity (codes: 278.0x);
5. Cardiovascular and neurological diseases: cardiac
arrhythmias (ICD-9 CM codes: 426.0, 426.1x, 426.7,
426.9, 427.0–427.4x, 427.6x, 427.8x, 427.9, 785.0,
996.01, 996.04, V45.0x, and V53.3x); cerebrovascular
disease (codes: 430–438.xx); coronary artery disease
(codes: 410.xx–414.xx); heart failure (codes: 428.x);
hypertension (codes: 401.x); peripheral vascular dis-
ease (codes: 441.9, 443.9, 785.4, and V434); epilepsy
(codes: 345.xx)
6. Gastroenterology and hepatology: kidney stone (ICD-9
CM codes: 592.0); liver disease (codes: 571.2, 571.4x–
571.6); peptic ulcer disease (codes: 531.xx–534.xx);
renal disease (codes: 582.xx, 583.0–583.2, 583.4,
583.6, 583.7, 585, 586, and 588.x).
For each subject, outpatient and/or inpatient diagnoses
of these disorders during the study period would be ana-
lyzed. Demographics and clinical variables were compared
between migraine cases and controls using the Chi-square
test or student’s t test when appropriate. We have
employed the odds ratio (OR) with 95 % confidence
interval to quantify the risk of a co-morbidity of migraine
in different groups of patients. All tests were two-tailed,
and p values of \0.05 were considered significant.
2.6 The analysis procedure
The analysis procedure consists of two stages. During the
first stage, the RVKDE algorithm was invoked to construct
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one approximate probability density function for the cases,
denoted by f^ , and another probability density function for
the controls, denoted by f^ 0. Then, all the cases were
examined one by one. Let si denote the feature vector
corresponding to the i-th case in the dataset. If f^ ðsiÞ=f^ 0ðsiÞ
is greater than a threshold, then the case was labeled as
sample of interest. As mentioned earlier, this screening
process aimed to identify those cases that shared some
distinctive features in comparison with the controls.
During the second stage, the G2DE algorithm was
invoked to cluster the cases of interest and provided sum-
marized descriptions of the clusters. However, as men-
tioned earlier, the number of features, which correspond to
the dimension of the vector space and thus the dimension
of the covariance matrix output by the G2DE algorithm,
should be limited to a small integer for us to easily obtain
an abstract image of the underlying distribution. Accord-
ingly, we incorporated a feature selection process before
invoking the G2DE algorithm. The feature selection pro-
cess proceeded as follows. First, the correlation matrix of
the original ten features is derived based on the cases of
interest identified in the first stage of analysis. Then, those
eigenvectors with the corresponding eigenvalue larger than
1 are selected to form the factor space. Finally, the factor
space is rotated orthogonally and the component features of
the rotated factors with a loading larger than 0.4 are
selected to form a subspace into which the original dataset
is projected.
3 Results
Table 1 shows the demographics of the entire dataset,
which includes 19,356 migraine cases and 96,780 controls.
As expected, the distributions of ages and genders are
identical among migraine cases and controls. Furthermore,
both for preventive medicines (i.e., amitriptyline, flunari-
zine, propranolol, topiramate, and valproic acid) and relief
treatment of migraine (i.e., ergotamine), case patients have
significant higher proportions of utilization than control
samples. However, for propranolol, topiramate, and val-
proic acid, case patients have lower exposure dosages and
durations. It is observed that the mean prescription dosage
of migraine medication in the current study follows the
corresponding DDD (B1 DDD per day).
Figure 1 shows the results obtained with the conventional
analysis procedure, i.e., without invoking the proposed
density estimation-based procedure. The blue bars show the
relative risks of suffering co-morbidities among migraine
cases and controls. The odds ratios with respect to the
following co-morbidities are: alcohol abuse 1.8/1.67, anxi-
ety state 3.14/3.36, bipolar disorder 2.11/2.6, depression
3.2/3.53, drug abuse 2.96/4.17, psychoses 1.53/1.5, allergic
rhinitis 2.19/2.34, chronic pulmonary disease 1.94/1.84,
Meniere’s disease 4.03/3.89, low back pain 2.07/2.04, neck
pain 2.58/2.78, neck sprain 2.25/2.18, pain syndrome 2.28/
2.25, rheumatoid arthritis 2.03/2.13, spinal disk herniation
2.21/2.39, diabetes mellitus 1.16/1.15, fluid electrolyte dis-
order 1.78/1.56, hyperlipidemia 1.6/1.6, hypothyroidism
1.61/1.77, obesity 1.73/1.94, cardiac arrhythmias 2.17/2.03,
cerebrovascular disease 2.55/2.34, coronary artery disease
1.82/1.77, heart failure 1.49/1.34, hypertension 1.6/1.61,
peripheral vascular disease 2.09/2.25, epilepsy 2.74/2.42,
kidney stone 1.92/1.83, liver disease 1.74/1.74, peptic ulcer
disease 2.33/2.33, and renal disease 1.5/1.45. The data pre-
sented in Fig. 1 reveal that migraine patients were more
likely than age- and sex-matched controls to suffer these
illnesses. Please refer to Supplementary Table 1 for more
detailed statistics.
The red bars in Fig. 1 with the detailed data in Sup-
plementary Table 2 show the relative risks of suffering
co-morbidities between the migraine cases classified as
samples of interest during the first stage of the proposed
analysis procedure and their age- and sex-matched con-
trols. In this respect, the RVKDE algorithm identified
7,146 migraine patients as samples of interest. Based on the
data shown in Fig. 1 and the statistics shown in Supple-
mentary Tables 1 and 2, we can conclude that those
migraine cases of interest suffered even higher risks of
co-morbidities.
According to the demographics shown in Table 2, the
7,146 cases of interest have lower male proportion than the
remaining 12,210 migraine cases (24.8 vs. 29.1 %;
p \ 0.001). Moreover, the mean age of the cases of interest
is older than the mean age of the remaining migraine cases,
45.3 versus 41.8 with p value\0.001. For both preventive
medicines and relief treatment of migraine, cases of
interest have significant higher utilization proportions than
the remaining migraine patients. However, for topiramate
and valproic acid, the cases of interest have lower exposure
dosages and durations. Figure 2 and Supplementary
Table 3 show the relative risks of co-morbidities among
the cases of interest and the remaining migraine cases. We
observed that the cases of interest suffered higher risks of
co-morbidities than the remaining migraine patients.
Since Figs. 1 and 2 (and Supplementary Tables 2, 3)
confirm that the first stage of the proposed analysis pro-
cedure successfully identified a subset of migraine cases
who suffered higher risks of developing co-morbidities
according to characteristics of medication exposure, it is
highly desirable to conduct an in-depth analysis. Accord-
ingly, in the second stage of the proposed analysis proce-
dure, the G2DE algorithm was invoked to identify the main
clusters among the 7,146 cases of interest. As mentioned
earlier, before invoking the G2DE algorithm, factor
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analysis was carried out to identify the most informative
features. In this respect, it must be noted that the set of
cases of interest passed the two criteria commonly adopted
to measure the adequacy of applying factor analysis. In
fact, applying the Kaiser–Meyer–Olkin (KMO) test on the
set of cases of interest yielded a value of 0.502, which is
higher than the commonly adopted threshold of 0.5, and
applying the Bartlett’s test yielded a value smaller than
0.001, which is significant for variance homogeneity. The
end result of the factor analysis is that exposure dosages (in
unit of milligram) for the five preventive medicines of
migraine: amitriptyline, flunarizine, propranolol, topira-
mate, and valproic acid, were selected respectively.
The G2DE algorithm identified two clusters with dis-
tinctive characteristics shown in Table 3. Comparing the
cases in cluster 0 and cluster 1, we can find that the cases in
cluster 1 were generally older (52.5 vs. 44.7 with p value
\0.001) but they have almost the same gender distribution.
Furthermore, for both preventive medicines and relief
treatment of migraine attacks, the case samples in cluster 1
had significant larger exposure dosages and longer dura-
tions. According to the results shown in Fig. 3 and
Table 1 Demographics of the
dataset
Variable Migraine (n = 19,356) (%) Control (n = 96,780) (%) p value
Male 5,328 (27.5) 26,640 (27.5) 1.000
Follow-up migraine 3,664 (18.9) 0 \0.001
Age (years)
B50 13,530 (69.9) 67,650 (69.9) 1.000
51–64 3,724 (19.2) 18,620 (19.2)
C65 2,102 (10.9) 10,510 (10.9)
Drug medication
Amitriptyline 211 (1.1) 335 (0.3) \0.001
Dosage (mg) (SD) 1,506.3 (3,101) 2,393.1 (6,903.6) 0.073
Duration (day) (SD) 54.6 (90.4) 73.6 (153.1) 0.096
Dosage (DDD) (SD) 20.4 (41.8) 33.5 (96.0) 0.056
Average dosage (DDD) (SD) 0.4 (0.2) 0.5 (0.5) 0.01
Flunarizine 2,533 (13.1) 2,406 (2.5) \0.001
Dosage (mg) (SD) 375.2 (704.0) 301.7 (796.8) \0.001
Duration (day) (SD) 49.3 (92.4) 34.8 (86.9) \0.001
Dosage (DDD) (SD) 37.5 (70.4) 30.2 (79.7) \0.001
Average dosage (DDD) (SD) 0.9 (0.5) 1.1 (0.6) \0.001
Propranolol 6,626 (34.2) 10,011 (10.3) \0.001
Dosage (mg) (SD) 2,359.9 (5,604.7) 2,746.3 (6,607.6) \0.001
Duration (day) (SD) 89.4 (175.6) 109.4 (216.2) \0.001
Dosage (DDD) (SD) 14.8 (35.5) 17.2 (41.4) \0.001
Average dosage (DDD) (SD) 0.2 (0.1) 0.2 (0.2) 0.003
Topiramate 428 (2.2) 96 (0.1) \0.001
Dosage (mg) (SD) 9,419.6 (45,071.2) 42,088.8 (79,385.5) \0.001
Duration (day) (SD) 87.6 (156.0) 283.2 (405.7) \0.001
Dosage (DDD) (SD) 31.4 (150.3) 140.3 (264.6) \0.001
Average dosage (DDD) (SD) 0.2 (0.2) 0.4 (0.4) \0.001
Valproic acid 113 (0.6) 136 (0.1) \0.001
Dosage (mg) (SD) 54,053.5 (116,266.7) 93,832.7 (132,227.4) 0.013
Duration (day) (SD) 91.0 (150.3) 140.3 (201.6) 0.033
Dosage (DDD) (SD) 36.0 (77.5) 62.6 (88.2) 0.013
Average dosage (DDD) (SD) 0.4 (0.3) 0.5 (0.3) 0.002
Ergotamine 6,088 (31.5) 2,575 (2.7) \0.001
Dosage (mg) (SD) 57.4 (184.1) 21.5 (81.9) \0.001
Duration (day) (SD) 37.0 (94.2) 13.5 (46.5) \0.001
Dosage (DDD) (SD) 14.8 (46.7) 6.7 (27.8) \0.001
Average dosage (DDD) (SD) 0.5 (0.3) 0.6 (0.6) \0.001
Application of density estimation algorithms 99
123
Fig. 1 Relative risks of co-morbidities among migraine cases and
controls a for the study period of 24 months before the index date,
and b for the study period of 12 months after the index date. The blue
bars represent values for original subjects, and the red bars represent
values for samples of interest (color figure online)
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Supplementary Table 4, cases in cluster 1 had higher risks
of suffering mental disorders [odds ratio (OR): alcohol
abuse 2.31/2.77, anxiety state 2.68/1.81, bipolar disorder
5.12/5.27, depression 2.57/2.5, drug abuse 5.26/6.02, and
psychoses 4.22/3.61], diabetes mellitus (OR = 2.1/2.09),
fluid electrolyte disorder (OR = 2.51/2.59), and cardio-
vascular/neurological diseases (OR: cardiac arrhythmias
1.77/1.63, cerebrovascular disease 2.26/2.38, coronary
artery disease 2.11/1.83, hypertension 2.4/2.34, and epi-
lepsy 3.55/3.88).
4 Discussions
4.1 Co-morbidities of migraine
According to the results shown in Fig. 1 and Supplemen-
tary Table 1, our study confirms co-morbid relationships
between migraine and various diseases even without car-
rying out the screening process to identify samples of
interest. In our study, the diseases included for co-mor-
bidity analysis can be classified into six categories.
Table 2 Demographics among
cases of interest and the
remaining migraine cases
Variable Of interest (n = 7,146) (%) Remaining (n = 12,210) (%) p value
Male 1,773 (24.8) 3,555 (29.1) \0.001
Follow-up migraine 1,636 (22.9) 2,028 (16.6) \0.001
Age (years)
B50 4,598 (64.3) 8,932 (73.2) \0.001
51–64 1,572 (22.0) 2,152 (17.6)
C65 976 (13.7) 1,126 (9.2)
Drug medication
Amitriptyline 205 (2.9) 16 (0.1) \0.001
Dosage (mg) (SD) 1,444.0 (2,534.8) 2,304.7 (7,274.7) 0.286
Duration (day) (SD) 54.7 (89.0) 53 (109.3) 0.943
Dosage (DDD) (SD) 19.6 (34.4) 30.7 (97.0) 0.304
Average dosage (DDD) (SD) 0.4 (0.2) 0.3 (0.2) 0.239
Flunarizine 2,362 (33.1) 171 (1.4) \0.001
Dosage (mg) (SD) 396.8 (722.5) 76.6 (189.9) \0.001
Duration (day) (SD) 52.0 (94.8) 12.1 (29.5) \0.001
Dosage (DDD) (SD) 39.7 (72.3) 7.7 (19.0) \0.001
Average dosage (DDD) (SD) 0.9 (0.5) 0.9 (0.5) 0.411
Propranolol 5,840 (81.7) 786 (6.4) \0.001
Dosage (mg) (SD) 2,540.6 (5,866.7) 1,017.7 (2,654.5) \0.001
Duration (day) (SD) 92.8 (177.1) 63.4 (162.2) \0.001
Dosage (DDD) (SD) 15.9 (37.2) 6.4 (16.6) \0.001
Average dosage (DDD) (SD) 0.181 (0.129) 0.152 (0.098) \0.001
Topiramate 421 (5.9) 7 (0.1) \0.001
Dosage (mg) (SD) 8,822.9 (42,984.2) 45,307.1 (117,072.4) 0.034
Duration (day) (SD) 86.9 (153.2) 127.8 (295.7) 0.492
Dosage (DDD) (SD) 29.4 (143.3) 151.0 (390.2) 0.034
Average dosage (DDD) (SD) 0.2 (0.2) 0.5 (0.5) \0.001
Valproic acid 104 (1.5) 9 (0.1) \0.001
Dosage (mg) (SD) 43,163.0 (86,795.3) 179,900 (269,999.2) \0.001
Duration (day) (SD) 78.7 (117.7) 232.8 (336.8) 0.003
Dosage (DDD) (SD) 28.8 (57.9) 119.9 (180) \0.001
Average dosage (DDD) (SD) 0.3 (0.3) 0.6 (0.2) 0.001
Ergotamine 2,902 (40.6) 3,186 (26.1) \0.001
Dosage (mg) (SD) 71.4 (204.1) 44.6 (162.7) \0.001
Duration (day) (SD) 47.6 (105.4) 27.3 (81.5) \0.001
Dosage (DDD) (SD) 18.3 (51.5) 11.5 (41.5) \0.001
Average dosage (DDD) (SD) 0.4 (0.3) 0.5 (0.3) \0.001
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4.1.1 Mental disorders
The correlation between mental disorder and migraine has
been studied extensively in recent years and our results
match the previous observations. The American Migraine
Prevalence and Prevention (AMPP) study demonstrated
that both depression (OR = 2.0) and anxiety (OR = 1.8)
were included in the co-morbidity profiles of chronic
migraine and episodic migraine patients (Buse et al. 2010).
Based on the Italian version of the Mini International
Neuropsychiatry Interview (MINI), Beghi et al. (2010)
reported that significant proportions of depression and
moderate proportions of anxiety were among migraine and
tension-type headache patients. Dilsaver et al. (2009)
showed the association between bipolar disorder and
migraine by observing that patients with a family history of
bipolar disorder were 4.38 (OR = 4.38) times more likely
to have migraine headaches than those without. A recent
questionnaire survey revealed that migraine was far more
prevalent in the substance abusers, e.g., alcohol, benzodi-
azepine, or opioids (Beckmann et al. 2012). Because of
distinctness for study designs and data sources, we might
not directly compare our quantitative results with bench-
mark values from literatures. Nevertheless, our results in
Fig. 1 and Supplementary Table 1 confirm that migraine
patients are more likely than controls to suffer mental
disorders, which is in conformity with the observations
reported in previous studies. Shared serotonergic dysfunc-
tion between migraine and affective disorders may con-
tribute these associations.
4.1.2 Otolaryngology
The association between migraine and asthma has still been
under debate. The Head-HUNT study showed that both
migraine and non-migrainous headache were 1.5 times
(OR = 1.5) more prevalent among those with asthma than
those without (Aamodt et al. 2007). On the contrary, another
study showed that the risk of developing follow-up incident
asthma was not materially higher for migraine patients
(Becker et al. 2008). Our results support the co-morbid
associations between migraine and allergic rhinitis
(OR = 2.19/2.34) as well as chronic pulmonary disease
(OR = 1.94/1.84). Recent evidence has suggested that
activation and sensitization of primary afferent meningeal
nociceptive neurons trigger migraine attacks and the trig-
gering factor is the involvement of mast cells (Levy et al.
2006). These findings may explain why allergic nasal
symptoms accompany migraine. Finally, it has been repor-
ted that patients with Meniere’s disease suffered higher
prevalence of migraine and Meniere’s disease patients
with migraine suffered more severe vertigo or hearing loss
Fig. 2 Relative risks of co-morbidities among cases of interest and the remaining migraine cases for the study period of 24 months before the
index date (blue bars), and for the study period of 12 months after the index date (red bars) (color figure online)
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(Cha et al. 2007). Again, the results from our population-
based study are in conformity with these findings.
4.1.3 Musculoskeletal illnesses
The Nord-Trondelag Health Survey found that prevalence
of chronic headache was 4.6 times (OR = 4.6) higher
among individuals with musculoskeletal symptoms than
among those without (Hagen et al. 2002). Similarly, 92
Israeli consecutive patients with migraine from a tertiary
headache clinic suffered high incidence of fibromyalgia
syndrome (Ifergane et al. 2006). In addition, the National
Health Examination and Nutrition Survey (NHANES)
showed adults with headache/migraine suffered increased
odds of rheumatoid arthritis (OR = 1.95) (Kalaydjian and
Merikangas 2008). Our results in Fig. 1 and Supplementary
Table 1 confirm the co-morbid associations between
migraine and various musculoskeletal illnesses.
4.1.4 Metabolism and endocrinology
Results of any significant association between migraine
and diabetes are conflicting: some showed co-morbidity
(OR = 1.4) (Bigal et al. 2010), some not (Le et al. 2011),
Table 3 Demographics among
the clusters identified by G2DE
Variable Cluster 1 (n = 489) (%) Cluster 0 (n = 6,657) (%) p value
Male 134 (27.4) 1,639 (24.6) 0.169
Follow-up migraine 153 (31.3) 1,483 (22.3) \0.001
Age (years)
B50 216 (44.2) 4,382 (65.8) \0.001
51–64 167 (34.2) 1,405 (21.1)
C65 106 (21.7) 870 (13.1)
Drug medication
Amitriptyline 194 (39.7) 11 (0.2) \0.001
Dosage (mg) (SD) 1,524.0 (2,582.9) 32.5 (17.0) 0.057
Duration (day) (SD) 57.6 (90.7) 3 (1.2) 0.048
Dosage (DDD) (SD) 20.6 (35.0) 0.4 (0.2) 0.058
Average dosage (DDD) (SD) 0.4 (0.2) 0.1 (0.1) 0.001
Flunarizine 171 (35.0) 2,191 (32.9) 0.351
Dosage (mg) (SD) 2,055.4 (1,692.5) 267.4 (330.0) \0.001
Duration (day) (SD) 255.6 (220.8) 36.1 (49.2) \0.001
Dosage (DDD) (SD) 205.5 (169.2) 26.7 (33.0) \0.001
Average dosage (DDD) (SD) 0.9 (0.4) 0.9 (0.5) 0.499
Propranolol 373 (76.3) 5,467 (82.1) 0.001
Dosage (mg) (SD) 15,310.1 (16,078.8) 1,669.3 (2,699.2) \0.001
Duration (day) (SD) 438.2 (399.6) 69.3 (118.0) \0.001
Dosage (DDD) (SD) 96.6 (102.8) 10.4 (16.9) \0.001
Average dosage (DDD) (SD) 0.233 (0.175) 0.177 (0.124) \0.001
Topiramate 50 (10.2) 371 (5.6) \0.001
Dosage (mg) (SD) 44,320.5 (117,333.2) 4,038.8 (8,993.7) \0.001
Duration (day) (SD) 236.3 (301.4) 66.8 (105.8) \0.001
Dosage (DDD) (SD) 147.7 (391.1) 13.5 (30.0) \0.001
Average dosage (DDD) (SD) 0.327 (0.344) 0.181 (0.192) \0.001
Valproic acid 33 (6.7) 71 (1.1) \0.001
Dosage (mg) (SD) 112,018.2 (129,297.2) 11,159.9 (12,984.2) \0.001
Duration (day) (SD) 181.3 (160.8) 31.0 (36.2) \0.001
Dosage (DDD) (SD) 74.7 (86.2) 7.4 (8.7) \0.001
Average dosage (DDD) (SD) 0.5 (0.3) 0.3 (0.2) 0.002
Ergotamine 203 (41.5) 2,699 (40.5) 0.674
Dosage (mg) (SD) 170.3 (453.5) 63.9 (169.2) \0.001
Duration (day) (SD) 101.3 (174.8) 43.6 (97.1) \0.001
Dosage (DDD) (SD) 43.6 (113.6) 16.4 (42.8) \0.001
Average dosage (DDD) (SD) 0.5 (0.4) 0.4 (0.3) 0.24
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and yet the other reported an inverse association (Burn
et al. 1984). This debate may be why our results only show
a slight co-morbid association between migraine and dia-
betes mellitus (OR = 1.16/1.15). Similarly, the Interna-
tional Headache Society (IHS) Classification of Headache
Disorders Second Edition includes ‘‘Headache attributed to
hypothyroidism’’, and it was observed that approximately
30 % of 102 hypothyroid patients had bilateral, continuous
headache (Moreau et al. 1998). Our observations also
support this conclusion (OR = 1.61/1.77), but another
population-based study obtained a conflicting result with
negative correlation (OR = 0.5) (Hagen et al. 2001). Ele-
vated levels of cholesterol (OR = 5.97) and triglycerides
(OR = 4.42) had ever been reported to be associated with
migraine (Rist et al. 2011), but there is no direct significant
association between electrolyte imbalance and migraine as
far as we are concerned to support our results (OR = 1.78/
1.56). Finally, one epidemiologic study found the positive
association between migraine and obesity (Peterlin et al.
2010). This suggestion is also supported by our analyses
(OR = 1.73/1.94) while another population-based study
disputed the association (OR = 1.03) (Winter et al. 2009).
4.1.5 Cardiovascular and neurological diseases
For over one decade, it has been a consensus among bio-
medical scientists that migraine increases atherosclerosis
risk and ignites cardiovascular disorders such as instance
angina, ischemic heart disease (OR = 1.94–2.2), and
stroke (OR = 1.5–5.46) (Bigal et al. 2010; Kurth et al.
2008; Stang et al. 2005). Schurks et al. (2008) suggested
that the MTHFR 677TT genotype magnifies risk of car-
diovascular disease among migraine patients. Bigal et al.
(2010) demonstrated a higher cardiovascular risk profile
among migraine patients with higher cholesterol and blood
pressure level. On the other hand, the co-morbidity
between migraine and epilepsy has been suggested in one
recent Dutch study (OR = 1.39) (Nuyen et al. 2006). The
linkage between epilepsy and visual aura migraine possibly
results from a gene defect located at chromosome 9q21–
q22 (Deprez et al. 2007). In our population-based study, all
these cardiovascular/neurological illnesses were prevalent
among migraine patients than among matched controls.
4.1.6 Gastroenterology and hepatology
One recent study has concluded that kidney stone is a co-
morbidity of migraine (OR = 1.43) (Le et al. 2011), which
coincides with our analyses (OR = 1.92/1.83). It was sug-
gested that topiramate dosage, which is commonly used for
migraine preventive treatment, was inversely correlated to
urinary citrate excretion and led to increased risk of stone-
forming (Kaplon et al. 2011). On the other hand, Helico-
bacter pylori infection might be both causes of hepatic
Fig. 3 Relative risks of co-morbidities among the clusters identified by G2DE for the study period of 24 months before the index date
(blue bars), and for the study period of 12 months after the index date (red bars) (color figure online)
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encephalopathy and migraine symptoms in patients with
cirrhosis (Hong et al. 2007). Although non-steroidal anti-
inflammatory drugs, which are the symptomatic relief of
headache and migraine, may be ulcer-causing medications,
peptic ulcer disease did not have a high prevalence in the US
headache patients (Rozen and Fishman 2012). This is con-
tradictory to our observations for the co-morbid relation
between migraine and peptide-ulcer disease (OR = 2.33),
and prescriptions for drugs of headache relief without the
side effect of ulcer may explain this difference. Finally,
increased plasma concentrations of endothelin-1 had been
described in both migraine and renal disease patients; this
might be the reason for their co-morbid association (Noll
et al. 1996).
4.2 Analysis results of density estimation
The co-morbid associations of migraine and various kinds
of illnesses can be observed in Fig. 1 and Supplementary
Table 1. However, no matter comparing the 7,146 migraine
patients of interest extracted by RVKDE to their 35,730
age- and sex-matched controls, or to the remaining 12,210
migraine cases, they were even more likely to suffer these
co-morbid illnesses. Our study verifies the effectiveness of
density estimation algorithms on medical information
analyses. The extracted migraine ‘‘patients of interest’’ had
higher utilization proportions of both preventive medicines
and relief treatment for migraine than the filtered cases.
Because migraine is a common chronic, recurrent condi-
tion, it is believed that patients with significant medication
utilization are more representative for this disease. Since
some of the co-morbid illnesses studied belong to the
Charlson (Charlson et al. 1987) or Elixhauser index (Elix-
hauser et al. 1998), it is suggested that physicians screen
these patients for further risks of poor health conditions.
Moreover 489 of the 7,146 migraine cases of interest
could be identified by G2DE according to the characteris-
tics of medication exposures for migraine. Although for
flunarizine and ergotamine, the selected 489 cases and the
remaining 6,657 ones did not show significant differences
in utilization proportions, these migraine patients had lar-
ger exposure dosages and longer durations for all kinds of
drugs studied. This can be treated as a migraine severity
measurement. According to the results shown in Fig. 3 and
Supplementary Table 4, exposure dosage/duration of
medicines discriminates best for the mental disorders and
cardiovascular/neurological diseases. It was observed that
the worse the pain profile, the worse the physical func-
tioning and mental health (Wang et al. 2001). So our results
are in conformity with the previous conclusions.
Although conventional algorithms of regression analysis
are applicable for data mining in medical and/or clinical
information, they borrow the idea from multi-dimensional
contingency table to determine certain associations between
the dependent variable and the risk factors. Rather than fitting
a more saturated model, it might be more inclined to reflect an
interaction structure between the dependent variables and
corresponding risk factors. However, in this research, we
would like to refer the concept of discriminate analysis:
classifying an object that comes from one of two populations
having associated densities f1 and f2 could be based upon the
likelihood ratio f1/f2. It is expected that the significant dif-
ference between density distributions represents variances of
the dependent variables in distinct groups of independent
variable, e.g., an overall migraine severity measurement
quantified by synergistic medication exposures. In fact, we
ever categorized the migraine patients of interest as the con-
tingency table by age, but this clustering cannot discriminate
mental disorders the way G2DE can (data are not shown). So
the proposed density estimation-based analysis procedure
conceivably provides valuable insights which might be
overlooked by conventional methods.
4.3 Limitations
A major strength of our study was utilization of a large
population-based medical claims database, but there were
some limitations. First, administrative claims reported by
hospitals or clinics may be less accurate than clinical
diagnoses and observer-rating scales. Second, prescriptions
of medications for migraine do not guarantee drug adher-
ence. Third, the administrative claims data of NHIRD did
not include detailed personal information like body mass
index, living habits, or results of laboratory tests, which
might be important confounding factors. Finally, more
confounding factors of the outcome diseases, e.g., age, sex,
medication drugs, treatment procedures, or associated
symptoms, should be taken into account.
5 Conclusions
In recent years, data analysis based on large medical and
clinical databases has gained attention among biomedical
researchers. Furthermore, scientists have turned to exploit
advanced machine learning and/or data mining approaches
to extract valuable clues hidden in large medical and
clinical databases. In this paper, we have proposed a den-
sity estimation-based data analysis procedure to investigate
the co-morbid associations between migraine and the sus-
pected diseases by characteristics of medication exposure.
The primary objective of this study is to develop a novel
analysis procedure that can discover insightful knowledge
from large medical databases. The results obtained by
applying the proposed two-staged procedure to analyze co-
morbidities of migraine reveal that the proposed procedure
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can effectively identify a number of clusters of cases with
distinctive characteristics. Furthermore, it has been
observed that the distinctive characteristics of the clusters
are in conformity with the recently discovered knowledge
in biomedical research. Accordingly, it is conceivable that
the proposed analysis procedure will be exploited to pro-
vide valuable clues of pathogenesis and facilitate devel-
opment of proper treatment strategies.
Three further courses are undertaken. Firstly, since
effectiveness of the proposed analysis procedure has been
verified, this method will be exploited to investigate
characteristics of more epidemics, such as osteoporosis or
herpes zoster. Secondly, appropriate statistical tests will be
issued on the mined facts to strengthen persuasiveness of
this approach. Finally, application of various advanced
machine learning/data mining algorithms on medical and/
or clinical databases will also be studied.
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